Filters
Results 1 - 10 of 1159
Results 1 - 10 of 1159.
Search took: 0.028 seconds
Sort by: date | relevance |
Janevik-Ivanovska, E., E-mail: emilijajanevik@yahoo.com
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
AbstractAbstract
No abstract available
Primary Subject
Source
Mar 2010; 12 p; Technical meeting on therapeutic radiopharmaceuticals; Vienna (Austria); 16-20 Nov 2009; Published as PowerPoint presentation only; Working material
Record Type
Report
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Divgi, Chaitanya, E-mail: chaitanya.divgi@uphs.upenn.edu
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
AbstractAbstract
No abstract available
Primary Subject
Source
Mar 2010; 37 p; Technical meeting on therapeutic radiopharmaceuticals; Vienna (Austria); 16-20 Nov 2009; Published as PowerPoint presentation only; Working material
Record Type
Report
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Background: As systemic control of high-risk neuroblastoma (NB) has improved, relapse in the central nervous system (CNS) is an increasingly recognized entity that carries a grim prognosis. This study describes the use of craniospinal irradiation (CSI) for CNS relapse and compares outcomes to patients who received focal radiotherapy (RT). Methods: A retrospective query identified 29 children with NB treated at Memorial Sloan-Kettering Cancer Center since 1987 who received RT for CNS relapse. At CNS relapse, 16 patients received CSI (median dose, 2160cGy), and 13 received focal RT. Of those who underwent CSI, 14 (88%) received intra-Ommaya (IO) radioimmunotherapy (RIT); one patient in the non-CSI cohort received IO-RIT. Results: Patient characteristics were similar between the groups. Time to CNS relapse was 20 and 17 months for the CSI and non-CSI cohorts, respectively. At a median follow-up of 28 months, 12 patients (75%) in the CSI group are alive without CNS disease, including two patients with isolated skeletal relapse. Another patient is alive without disease after a brain relapse was retreated with RT. Three patients died-one with no NB at autopsy, one of CNS disease, and one of systemic disease. The two patients who died of NB did not receive IO-RIT. All 13 patients in the non-CSI cohort died at a median of 8.8 months. Conclusions: Low-dose CSI together with IO-RIT provides durable CNS remissions and improved survival compared with focal RT and conventional therapies. Further evaluation of long-term NB survivors after CSI is warranted to determine the treatment consequences for this cohort.
Primary Subject
Source
S0360-3016(09)03107-1; Available from http://dx.doi.org/10.1016/j.ijrobp.2009.09.005; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016;
; CODEN IOBPD3; v. 78(3); p. 849-854

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Full text of publication follows. The role of International Atomic Energy Agency (IAEA) is to promote pacific applications of nuclear energy and radioactivity that may help to improve the economic and social levels in Member States. In this respect, the improvement of national health care systems through the introduction of new diagnostic and therapeutic approaches developed within the field of nuclear medicine is one of its major goals. Finding effective cancer treatments is still at the forefront of IAEA projects due to the global impact of this disease. At the most fundamental level, cancer can be viewed as a perfect example of 'molecular disease' originating when the inner biochemical fabric of the cell is abnormally altered. It is exactly the complexity of this molecular machinery that makes the understanding and treatment of cancer so difficult. However, in the search for a consistent therapeutic approach, this basic molecular paradigm cannot be escaped. In this context, radionuclide therapy employing single-molecule radiolabelled substances still constitutes a promising tool for cancer treatment due to its intrinsic molecular nature. Radionuclide therapy is unique in its ability to deliver selectively to cancerous cells a therapeutic dose of radioactivity by means of rationally designed molecular carriers. Thus, a key advantage of molecular radionuclide therapy is that it does not need to achieve the full molecular picture, but just some relevant piece of the entire puzzle that may allow targeting selectively tumour cells. The major challenge is to find a perfect matching between the molecular properties of a radiolabeled agent and a relevant bio-molecular mechanism capable of uploading the required amount of radioactivity at the tumour site. In this respect, iodine-131 based therapy still remains a unique, unmatched example. IAEA is constantly promoting projects and scientific discussions on the applications of therapeutic radiopharmaceuticals in oncology. These programmes are pursued through different mechanisms such as the organization of Technical Projects, Coordinated Research Projects and Technical Meetings, and by supporting scientific conferences and symposia on selected topics. The ultimate goal is always to assist Member States in expanding their knowledge and favouring applications of effective target-specific radiopharmaceuticals that may provide a real benefit for the early detection and treatment of different type of cancers. (author)
Primary Subject
Source
Laboratoire Subatech, 4 rue Alfred Kastler, 44307 Nantes (France); 171 p; 2015; p. 95; WIPR 2013: Radiopharmaceuticals - from research to industry; Nantes (France); 9-12 Jul 2013; Available in abstract form only, full text entered in this record
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
Casaco Parada, Angel, E-mail: casaco@cim.sld.cu
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
AbstractAbstract
No abstract available
Primary Subject
Source
Mar 2010; 34 p; Technical meeting on therapeutic radiopharmaceuticals; Vienna (Austria); 16-20 Nov 2009; Published as PowerPoint presentation only; Working material
Record Type
Report
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Cacchione, R., E-mail: rcacchione@cemic.edu.ar
Conferences [25. Alasbimn Congress 2015; 5. Subimn congress; 2. latin american meeting of radiochemical]2015
Conferences [25. Alasbimn Congress 2015; 5. Subimn congress; 2. latin american meeting of radiochemical]2015
AbstractAbstract
[en] This presentation is about the radiotherapy, chemo-immunotherapy and radioimmunotherapy treatment. Its adequate response in Non-Hodgkin Lymphoma as well as the tolerance and reversibly hematologic toxicity
Original Title
Radioinmunoterapia
Primary Subject
Source
Asociación Latinoamericana de Sociedades de Biología y Medicina Nuclear-Alasbimn, Montevideo (Uruguay); 1 p; Nov 2015; 47 p; 25. Alasbimn Congress 2015; 25. Congreso Alasbimn 2015; Punta del Este (Uruguay); 18-21 Nov 2015; 5. Subimn congress; 5o. congreso de la Subimn; Punta del Este (Uruguay); 18-21 Nov 2015; 2. Latin-American meeting of radiochemical; 2o. encuentro latinoamericano de radiofarmacia; Punta del Este (Uruguay); 18-21 Nov 2015; Available from: http://www.alasbimn2015.org.uy/
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] Molecular targeting may be defined as the specific concentration of a diagnostic or therapeutic tracer by its interaction with a molecular species that is distinctly present or absent in a disease state. Monoclonal antibody (mAb) is one of the successful agents for targeted therapy in cancer. To enhance the therapeutic effect. the concept of targeting radionuclides to tumors using radiolabeled mAbs against tumor-associated antigens, radioimmunotherapy, was proposed. The efficacy of radioimmunotherapy, however, has to be further optimized. Several strategies to improve targeting of tumors with radiolabeled mAbs have been developed, such as the use of mAb fragments, the use of high-affinity mAbs, the use of labeling techniques that are stable in vivo, active removal of the radiolabeled mAb from the circulation, and pretargeting strategies. Until now, however, there are many kinds of obstacles to be solved in the use of mAb for the targeted therapy. Major technical challenges to molecular targeting are related to the rapid and specific delivery of tracers to the target, the elimination of unwanted background activity, and the development of more specific targets to create a cytocidal effect. Further development of this field will be determined by success in solving these challenges
Primary Subject
Source
51 refs, 7 figs, 5 tabs
Record Type
Journal Article
Journal
Nuclear Medicine and Molecular Imaging; ISSN 1975-129X;
; v. 40(2); p. 74-81

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Ryan, Davinia; Bodei, Lisa, E-mail: ryand4@mskcc.org, E-mail: bodeil@mskcc.org2017
AbstractAbstract
[en]
Purpose of Review
Radioimmunotherapy (RIT) is the targeting of radiosensitive tumors through the use of monoclonal antibodies. The purpose of this review is to discuss the benefit and challenges of RIT. We appraise factors that determine optimal targeting of tumor such as choice of target, targeting antibody, and the associated radionuclide, as well as the current methods to potentiate RIT effect.Recent Findings
Radioimmunotherapy has a well-established role in the treatment of hematological malignancies. Recent completed and current studies in the treatment of solid malignancies are however demonstrating good clinical response with acceptable toxicity profiles.Summary
Since its inception, improved molecular engineering and targeting of new molecules, the discovery of new potential tumor targets, and the incorporation of methods to potentiate effect and reduce toxicity, will probably see radioimmunotherapy becoming a more commonplace treatment in the management of both hematological and solid malignancies.Primary Subject
Source
Copyright (c) 2017 Springer Science+Business Media, LLC; http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Current Radiology Reports; ISSN 2167-4825;
; v. 5(12); p. 1-9

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] A method is disclosed of treating solid tumor cancer in a living being by prolonging the time a therapeutically effective agent remains in the tumor. The method comprises the steps of selecting particles of an aggregated protein and injecting them interstitially into the tumor. The therapeutically effective agent selected from the group consisting of radioactive antibodies and radioactive growth factors is injected into the tumor either after the injection of the proteinaceous particles, or simultaneously. 7 figs
Primary Subject
Source
23 Jul 1996; 19 Jan 1994; [10 p.]; US PATENT DOCUMENT 5,538,726/A/; US PATENT APPLICATION 8-183,463; Available from Patent and Trademark Office, Box 9, Washington, DC 20232 (United States); Application date: 19 Jan 1994
Record Type
Patent
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
No abstract available
Original Title
Efficacite biologique a long terme de la radioimmunotherapie en deux temps dans le traitement du cancer medullaire de la thyroide
Primary Subject
Source
41. colloquium of nuclear medicine in French language; 41. colloque de medecine nucleaire de langue francaise; Tours (France); 15-17 Oct 2003
Record Type
Journal Article
Literature Type
Conference
Journal
Medecine Nucleaire. Imagerie Fonctionnelle et Metabolique; ISSN 0928-1258;
; CODEN MNIMEX; v. 27(no.9); p. 429

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
1 | 2 | 3 | Next |